<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842360</url>
  </required_header>
  <id_info>
    <org_study_id>MV130-SLG-001</org_study_id>
    <secondary_id>2012-003253-28</secondary_id>
    <nct_id>NCT01842360</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>MV130</acronym>
  <official_title>Randomized Double-blind Placebo-controlled Prospective, Parallel, Multicentre Clinical Trial of Bacterial Vaccine Administered by Sublingual Mucosa in Subjects With COPD for Efficacy and Safety Evaluation and Immunomodulatory Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inmunotek S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inmunotek S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of a biological vaccine
      (MV130 in subjects with Chronic Obstructive Pulmonary Disease (COPD) compared with a placebo
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind parallel placebo controlled study. The subjects will receive medication during
      12 months and will be followed up during another six months
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in the number of COP exacerbations.</measure>
    <time_frame>18 months</time_frame>
    <description>Average reduction of COP exacerbations at 18 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of COPD exacerbations</measure>
    <time_frame>18 months</time_frame>
    <description>Review of COPD exacerbations episodes severity per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First COPD exacerbation</measure>
    <time_frame>18 months</time_frame>
    <description>When takes place the First COPD exacerbation for every single patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication consumption</measure>
    <time_frame>18 months</time_frame>
    <description>Review of medication consumed from the beginning to the end of the COPD exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health resource consumption</measure>
    <time_frame>18 months</time_frame>
    <description>Counting the Health resource consumption due to COPD exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the emergency service</measure>
    <time_frame>18 months</time_frame>
    <description>Counting the number of visits to the emergency service due to COPD exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations due to COPD exacerbations</measure>
    <time_frame>18 months</time_frame>
    <description>Counting the number of hospitalization days due to COPD exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in COPD Assessment Test (CAT)</measure>
    <time_frame>18 months</time_frame>
    <description>Compare the COPD Assessment Test results at the beginning and at the end of the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in immunological parameters</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Specific Humoral Response (Serum immunoglobulin G against the vaccine bacterial antigens; salivary immunoglobulin A concentrations versus vaccine antigens) by ELISA.
Specific proliferative response of T cells (cluster of differentiation3 + / cluster of differentiation 4 + and cluster of differentiation 3 + / cluster of differentiation 8 +) in vitro following stimulation with bacterial antigens comprising the vaccine) by (carboxyfluorescein diacetate succinimidyl ester) CFSE labeling and flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>18 months</time_frame>
    <description>Review of the number of adverse event per patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>MV130</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive daily dose of MV130 during 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects will receive daily dose of placebo during 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The subjects will receive daily dose of placebo during 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MV130</intervention_name>
    <description>The subjects will receive daily dose of MV130 during 12 months</description>
    <arm_group_label>MV130</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Both gender

          -  Age between 35 and 85.

          -  Must be able to follow the treatment regimen

          -  Diagnosis of moderate COPD according to GOLD criteria

          -  Consumption of 10 or more packs of cigarettes/year

          -  Fertile women of must use an approved contraceptive method

        Exclusion Criteria:

          -  Pregnant women, breastfeeding

          -  Subject who has participated in a study or clinical trial with an investigational
             product in the last 3 months before inclusion

          -  Subject with severe COPD

          -  Subject with a history of hypersensitivity to any component of the vaccine

          -  Subject outside of age range

          -  Subject diagnosed with asthma

          -  Subject who has had an exacerbation 4 weeks before starting the trial.

          -  Subject that have needed corticosteroids in the last 4 weeks before starting the trial

               -  Subject diagnosed with Primary or Secondary Immunodeficiency Subjects with
                  chronic lymphoproliferative disease

               -  Subjects with chronic infectious disease

               -  Subject with chronic heart disease, arrhythmias, or episodes of arrhythmia
                  secondary to the administration of bronchodilators.

               -  Subject diagnosed with COPD and chronic colonization by Pseudomonas aeruginosa
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Fernández-Cruz, MD-PhD-prof</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_official>
    <last_name>Javier Miguel Díez, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>José Luis Alvarez-Salas, MD-PhD-prof,</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>María Jesús Buendía, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Carlos José Álvarez, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Soledad Alonso, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Francisco García, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Joan Serra, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Vic</name>
      <address>
        <city>Vic</city>
        <state>Barcelona</state>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Torrejon</name>
      <address>
        <city>Torrejón de Ardoz</city>
        <state>Madrid</state>
        <zip>28850</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Chronic obstructive pulmonary disease (COPD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

